首页> 美国卫生研究院文献>Drug Delivery >Synchronous delivery of oxygen and photosensitizer for alleviation of hypoxia tumor microenvironment and dramatically enhanced photodynamic therapy
【2h】

Synchronous delivery of oxygen and photosensitizer for alleviation of hypoxia tumor microenvironment and dramatically enhanced photodynamic therapy

机译:同步输送氧气和光敏剂以缓解缺氧肿瘤微环境并显着增强光动力疗法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Photosensitizer, proper laser irradiation, and oxygen are essential components for effective photodynamic therapy (PDT) in clinical cancer therapy. However, native hypoxic tumoral microenvironment is a major barrier hindering photodynamic reactions in vivo. Thus, we have prepared biocompatible liposomes by loading complexes of oxygen-carrier (hemoglobin, Hb) and photosensitizer (indocyanine green, ICG) for enhanced PDT against hypoxic tumor. Ideal oxygen donor Hb, which is an oxygen-carried protein in red blood cells, makes such liposome which provide stable oxygen supply. ICG, as a photosensitizer, could transfer energy from lasers to oxygen to generate cytotoxic reactive oxygen species (ROS) for treatment. The liposomes loading ICG and Hb (LIH) exhibited efficient tumor homing upon intravenous injection. As revealed by T2-weighted magnetic resonance imaging and immunohistochemical analysis, the intratumoral hypoxia was greatly alleviated, and the level of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in tumor was obviously down-regulated. A weak PDT efficiency was found in cells incubated in simulated hypoxia condition in vitro, while PDT effect was dramatically enhanced in LIH treated hypoxia cells under near-infrared (NIR) laser, which was mainly attributed to massive generation of ROS with sufficient oxygen supply. ROS trigger oxidative damage of tumors and induce complete suppression of tumor growth and 100% survival rate of mice, which were also in good health condition. Our work highlights a liposome-based nanomedicine that could effectively deliver oxygen to tumor and alleviate tumor hypoxia state, inducing greatly improved efficacy compared to conventional cancer PDT and demonstrates the promise of modulating unfavorable tumor microenvironment with nanotechnology to overcome limitations of cancer therapies.
机译:光敏剂,适当的激光照射和氧气是临床癌症治疗中有效光动力疗法(PDT)的重要组成部分。然而,天然缺氧的肿瘤微环境是阻碍体内光动力反应的主要障碍。因此,我们通过负载氧载体(血红蛋白,血红蛋白)和光敏剂(吲哚菁绿,ICG)的复合物来制备生物相容性脂质体,以增强针对缺氧肿瘤的PDT。理想的供氧体Hb是红细胞中的一种携氧蛋白,可制成提供稳定氧气供应的脂质体。 ICG作为一种光敏剂,可以将激光中的能量转移到氧气上,从而产生细胞毒性的活性氧(ROS)进行治疗。负载ICG和Hb(LIH)的脂质体在静脉注射后表现出有效的肿瘤归巢。 T2加权磁共振成像和免疫组织化学分析显示,肿瘤内的缺氧得到了很大程度的缓解,肿瘤中的缺氧诱导因子-1α(HIF-1α)和血管内皮生长因子(VEGF)水平明显下调。在体外模拟缺氧条件下孵育的细胞中发现PDT效率较弱,而LIH处理的缺氧细胞在近红外(NIR)激光下PDT效果显着增强,这主要归因于大量产生ROS并提供了充足的氧气。 ROS引发肿瘤的氧化损伤,并完全抑制肿瘤的生长和小鼠100%的存活率,它们也处于良好的健康状态。我们的工作突出了一种基于脂质体的纳米药物,该药物可以有效地向肿瘤输送氧气并减轻肿瘤的缺氧状态,与传统的癌症PDT相比,可大大提高疗效,并证明了利用纳米技术调节不利的肿瘤微环境以克服癌症疗法的局限性的希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号